Vir Biotechnology, Inc.
Financials
Valuation Metrics
Vir Biotechnology, Inc.'s Market Cap is $1.84B. At end of 2025 it was $840M. Ranked #2091 of 3,121 in US market (top 67%), #813 of 1,463 on NASDAQ (top 56%), #149 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 56%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.84B | US#2,091/3,121 Sec#149/266 |
| Revenue | $303M | US#2,457/3,121 Sec#97/266 |
| Net Income | $-252M | US—/3,121 Sec—/266 |
| Total Assets | $1.21B | US#2,389/3,121 Sec#86/266 |
| Net Assets | $982M | US#1,779/3,121 Sec#68/266 |
| Employees | 367 | US#2,368/3,121 Sec#102/266 |
| Value | ||
| P/B | 1.87x | US#1,147/3,121 Sec#41/266 |
| P/S | 6.07x | US#2,443/3,121 Sec#89/266 |
| FCF Yield | -18.00% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -25.62% | US#2,538/3,121 Sec#107/266 |
| ROA | -20.72% | US#2,805/3,121 Sec#130/266 |
| Op. Margin | -88.97% | US#2,727/3,121 Sec#120/266 |
| Revenue Growth | 1495.93% | US#16/3,121 Sec#9/266 |
| Financial Health | ||
| Debt Ratio | 23.65% | US#265/3,121 Sec#89/266 |
| Total Debt | $93M | US#2,460/3,121 Sec#124/266 |
| FCF | $-332M | US#2,862/3,121 Sec#236/266 |
| Cash | $279M | US#1,474/3,121 Sec#85/266 |
| Current Ratio | 6.04x | US#394/3,121 Sec#125/266 |
| Performance | ||
| 1Y Return | 127.50% | US#143/3,121 Sec#50/266 |
| 1M Return | 15.07% | US#142/3,121 Sec#17/266 |
| From 52W High | -8.54% | US#595/3,121 Sec#43/266 |
| 1Y MDD | -25.61% | US#1,097/3,121 Sec#57/266 |
| Trading | ||
| Volume | 1,766,546 shares | US#927/3,121 Sec#95/266 |
| Trading Value | $19M | US#1,895/3,121 Sec#147/266 |
| Per Share | ||
| EPS | $-1.49 | US—/3,121 Sec—/266 |
| BPS | $5.83 | US#2,214/3,121 Sec#117/266 |
Company Info
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.